AI Article Synopsis
- The use of embolization has broadened beyond its initial application for hemorrhage and vascular malformations to treat conditions like uterine fibroids and benign prostatic hyperplasia.
- Various particulate embolic agents are being compared for their effectiveness in uterine fibroid and prostate artery embolization, suggesting that their unique properties can lead to different treatment outcomes.
- The article also discusses periprocedural pharmacology and protocols that allow patients to be discharged on the same day after these procedures.
Article Abstract
The scope of conditions managed by embolization, which was initially used for the treatment of hemorrhage and vascular malformations, is constantly expanding. Apart from oncologic indications, embolization is used to treat a wide range of benign pathology, including uterine fibroids and benign prostatic hyperplasia. While various particulate embolic agents are successfully used for benign embolization, there is growing evidence that unique properties of these may result in different outcomes. This article reviews available evidence comparing various particles used for uterine fibroid embolization and prostate artery embolization. In addition, we provide an overview of periprocedural pharmacology and protocols facilitating same-day discharge for these interventions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671682 | PMC |
| http://dx.doi.org/10.1055/s-0042-1758077 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!